In the pharmaceutical industry, robust control of equipment, facilities and processes is essential to ensure patient safety, product quality and regulatory compliance. In this context, the terms qualification and validation are essential, but they are often used interchangeably, which can lead to confusion in project planning, audits and GMP inspections. Although they are closely related, represent activities with clearly differentiated purposes, scope and methodologies within the life cycle of a GxP system.
This article explains what distinguishes qualification from validation, when each applies, and how they fit into regulatory expectations. EMA, FDA and guides like GAMP 5.
1. Qualification: ensure that the equipment or system is installed and functions as designed
Qualification is the set of documented activities that demonstrate that an equipment, facility, computerized system or critical utility meets the defined specifications and operates in accordance with its design. His aim The main objective is not to demonstrate the performance of the process, but to ensure that the technical infrastructure is suitable, segura and it is under control.
The qualification is structured in the following stages according to the Annex 15 of the Guide to Standards for Correct Manufacturing of Medicines for Human and Veterinary Use:
- DQ (Design Qualification): Verifies that the proposed design meets user requirements (URS) and GMP.
- IQ (Installation Qualification): Documents that the system has been installed correctly according to plans, manuals and specifications.
- OQ (Operational Qualification): Confirms that the system is operating within established operating limits.
- PQ (Performance Qualification): Evaluates the operation of the system under real conditions of use, although in some models (such as GAMP 5 for computerized systems) this stage conceptually belongs to the validation of the process.
The qualification applies to:
- Process equipment (reactors, mixers, freeze dryers).
- GxP computerized systems (SCADA, PLC, MES, LIMS).
- Critical installations (HVAC, purified water, clean steam).
- Laboratory equipment under GLP or GMP.
Qualification demonstrates that “the system works as designed,” establishing the basis for any subsequent validation efforts.
2. Validation: demonstrate that the process is reproducible and fit for purpose
Validation has a broader scope and focuses on verifying that a process, analytical method, cleaning or computerized system is capable of produce consistent, reproducible results according to predefined criteria. While qualification evaluates “the system”, validation evaluates “the process”.
The main areas of validation in the pharmaceutical sector include:
- Process validation: demonstrates that a manufacturing process consistently produces a product according to specifications.
- Validation of analytical methods: accuracy, precision, linearity, specificity, robustness.
- Cleaning validation: ensures that waste levels are within acceptable limits.
- Validation of computerized systems (CSV/CSA): Ensures that the system adequately supports GxP processes, protects data integrity, and operates under control.
Validation is mandatory under GMP and is defined in references such as:
- I Q7, I Q8, I Q9, I Q10.
- EU GMP – Part I, Chapter 4 and Annex 15.
- FDA 21 CFR Parts 210/211, and Process Validation guides.
- GAMP 5 Second Edition in the case of computerized systems.
Validation demonstrates that the process “meets its intended purpose in a robust and reproducible manner.”
3. Relationships and differences between qualification and validation
Although interrelated, there are clear differences that affect project planning:
3.1. Key differences
| Aspect | qualification | Validation |
| Range | Equipment, facilities, GxP systems | Processes, methods, cleaning, software |
| Aim | Verify installation and operation according to design | Demonstrate reproducibility and process capability |
| Moment | Before routine use | Before and during routine operation |
| Regulatory bases | Anexo 15, feat 5 | ICH Q8-Q10, Process Validation FDA |
| Evidence | IQ/Oq/Pq (Según System) | Studies, protocols and validation batches |
| Result | “Fit for use” system | “Robust and controlled” process |
3.2. Relationship within the life cycle
Qualification and validation should not be understood as isolated or sequential offline activities, but rather as elements integrated within the complete life cycle of GxP equipment, facilities, systems and processes. This life cycle view is a principle largely reinforced by current regulatory guidance, especially EU GMP Annex 15, ICH Q10 and GAMP 5, and constitutes a clear expectation during regulatory inspections.
The qualification acts as the starting point of the life cycle, as it establishes the objective evidence that an equipment, installation or system has been correctly designed, installed and is capable of operating within controlled limits. Without this solid technical basis, any subsequent validation would be unfounded, since It could not be ensured that the process is executed on a reliable infrastructure and in accordance with specifications..
Once the system is qualified, validation relies directly on the qualification results to demonstrate that the computerized process, method or system fulfills its intended purpose in a consistent and reproducible manner. In this sense, validation does not replace qualification, but rather extends towards real and routine use, incorporating operational variables, loading conditions, personnel interaction and variability inherent to the process.
From a practical approach, the relationship between the two can be summarized as follows: the qualification answers the question “Is the system properly built and functioning as designed?”, while validation does so “Is the process used by that system capable of producing compliant results in a repeatable manner?”
This link remains active throughout the life of the system. Any significant change (whether a hardware modification, software update, critical parameter change, or process alteration) must be evaluated through a change control system, which will determine if it is necessary to repeat qualification activities, validation or both. In this way, the validated state is preserved and it is ensured that the evidence continues to be representative of operational reality.
In addition, periodic reviews (Periodic Review O Continued Process Verification) reinforce this long-term relationship, confirming that both the qualified system and the validated process continue to operate within established limits. This dynamic approach is key to demonstrating to authorities that the company is not just “validate once,” but is actively managing compliance throughout the entire lifecycle.
In short, qualification and validation are complementary phases of the same control strategy, inseparable from a regulatory point of view. Understanding their relationship within the life cycle allows organizations to design more efficient strategies, avoid unnecessary duplication and maintain solid, sustainable and defensible GMP compliance against audits and inspections.
4. Regulatory and operational impact: why distinguishing them does matter
Clearly differentiating between qualification and validation is not just an academic exercise; has direct implications on the efficiency of projects, the robustness of regulatory compliance and the Product security. In operational terms, understanding what corresponds to qualification and what corresponds to validation allows you to plan resources, times and efforts in proportion to the risk, avoiding duplication and unnecessary documentation overload.
From a regulatory perspective, agencies expect companies to be able to justify with technical evidence why a system is qualified before validating a process, and how each decision is aligned with GMP, ICH and GAMP 5 guidelines. This clarity facilitates inspections and audits, as it demonstrates a systematic approach and defensible, instead of reactive or improvised management.
Furthermore, a strategic understanding of this difference allows us to anticipate operational changes. For example, when upgrading equipment or a computerized system, you can accurately determine whether requalification is sufficient, whether the process needs to be revalidated, or whether both actions are required. This decision traceability ensures that product integrity and patient safety remain intact, while optimizing implementation costs and times.
Conclusion: two complementary concepts that support the GMP control status
Qualification and validation are distinct but interdependent processes, which form the basis of the control state required by GMP. Qualification ensures that systems and equipment are appropriately designed, installed and operate as intended. Validation confirms that processes relying on those systems produce results that are consistent, reliable, and appropriate for their intended use.
Correctly differentiating between the two allows us to build quality systems that are more efficient, defensible and aligned with international regulatory expectations. For pharmaceutical organizations, mastering this distinction is essential to ensure safe products, robust processes and a sustainable regulatory compliance.